ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability...

ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper
Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD)
and Comorbid Diseases

BLACK MOUNTAIN, N.C., June 24 /PRNewswire/ -- ALP Life Sciences, LLC (Company)
today announced the Nanoveson(TM) patent has been filed and the Nanoveson(TM)
whitepaper is available at www.ALPLifeSciences.com/wp. After completing
initial research, the Company is pursuing clinical trials and FDA regulatory
approval of Nanoveson(TM) as a prescription drug treatment for non-alcoholic
fatty liver disease (NAFLD).

Over 60 million adult Americans suffer from NAFLD and these numbers are rising
rapidly. There is no FDA approved NAFLD treatment. NAFLD is a global health
crisis. NAFLD is also associated with the metabolic syndrome and other life
threatening diseases. NAFLD is known to progress to more advanced liver
diseases such as non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and
liver cancer.

Nanoveson(TM) is a novel approach to treating and diagnosing liver diseases
and comorbid diseases utilizing the principles of Applied Lipid Polymorphism,
which includes a revolutionary application of nanobiotechnology in the area of
self-organizing lipid membranes. Nanoveson(TM) therapy utilizes only natural
compounds. The therapy triggers liver triglyceride remodeling into bile
phospholipids and lipid membrane fusion and aggregation in the intestines.
Molecular compounds including biliary phospholipids, arachidonic acid
metabolites, cholesterol, methyl metabolites, phthalate esters, and other
compounds sequestered in vesicle membranes are expected to be a rich source of
disease state biomarkers. Nanoveson(TM) also has the potential to provide
extensive support to the life sciences industry in the area of drug metabolism
testing.

Research has demonstrated that enterohepatic circulation is the mechanism that
maintains quantitative whole body homeostasis of arachidonic acid. There is
extensive research focused on blocking arachidonic acid metabolism along
cytochrome P450, leukotriene, prostaglandin, and thromboxane eicosanoid
pathways. Arachidonic acid metabolism is implicated in many inflammatory
diseases, including cardiovascular diseases, gastrointestinal diseases,
arthritis, asthma, diabetes and cancer. Nanoveson(TM) therapy may improve
enterohepatic circulation by removing excess triglyceride deposits in the
liver and improving bile flow; having a positive therapeutic impact on
arachidonic acid driven disease states by reducing arachidonic acid
availability for inflammatory metabolism. Orphan disease indication targets
for inflammatory diseases may be pursed through clinical trials focused on
arachidonic acid specific surrogate end points.

David K. Barker, Founder and CEO of ALP Life Sciences, LLC stated, "The
preliminary evidence for the Nanoveson(TM) hypotheses is very promising,
however, it should be emphasized that the complex mechanisms of action
triggered by Nanoveson(TM) must be quantified, and the efficacy for targeted
indications must be established by clinical trials." Barker added, "I'd like
to take this opportunity to acknowledge the many scientists and physicians
referenced in the Nanoveson(TM) whitepaper. Without their dedication to
medical research the preliminary research and hypotheses presented in the
Nanoveson(TM) whitepaper would not have been possible. However, nothing in
this release or in the whitepaper suggests referenced researchers endorse the
preliminary conclusions presented at this time."

ALP Life Sciences, LLC is a life sciences research and development company
focused on therapeutics and diagnostics based on the new and emerging science
of Applied Lipid Polymorphism. ALP Life Sciences, LLC is currently evaluating
strategic relationships in the area of principal investigators, clinical trial
facilities, medical school research partnerships, manufacturing,
commercialization, global licensing and partnering opportunities for therapy,
diagnostics and drug metabolism testing. Relationships with medical research
foundations, public institutes of health, and life sciences venture capital
firms are also being evaluated. Interested parties should contact ALP Life
Sciences, LLC.

SOURCE ALP Life Sciences, LLC

David K. Barker, Founder and CEO, ALP Life Sciences, LLC, Applied Lipid
Polymorphism, +1-828-215-0399, Contact@ALPLifeSciences.com,
www.ALPLifeSciences.com